CAS 131918-61-1
:Paricalcitol
Description:
Paricalcitol is a synthetic analog of vitamin D2, primarily used in the treatment of secondary hyperparathyroidism associated with chronic kidney disease. Its chemical structure allows it to bind to vitamin D receptors, promoting calcium absorption and regulating parathyroid hormone levels. Paricalcitol is characterized by its ability to reduce parathyroid hormone secretion without significantly increasing serum calcium levels, making it a preferred option in managing hyperparathyroidism in patients with renal impairment. The substance is typically administered via injection or orally, depending on the clinical scenario. It is known for its relatively low risk of causing hypercalcemia compared to other vitamin D analogs. Paricalcitol is also recognized for its favorable pharmacokinetic profile, which includes a longer half-life and effective tissue distribution. As with any medication, monitoring for potential side effects, such as hypercalcemia or hyperphosphatemia, is essential during treatment. Overall, paricalcitol plays a crucial role in managing mineral and bone disorders in patients with chronic kidney disease.
Formula:C27H44O3
InChI:InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
InChI key:InChIKey=BPKAHTKRCLCHEA-UBFJEZKGSA-N
SMILES:C[C@@]12[C@](\C(=C\C=C3C[C@@H](O)C[C@H](O)C3)\CCC1)(CC[C@@]2([C@@H](/C=C/[C@@H](C(C)(C)O)C)C)[H])[H]
Synonyms:- (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-Hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
- (1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-Octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
- (1R,3R,7E,17beta)-17-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethylhex-2-en-1-yl]-9,10-secoestra-5,7-diene-1,3-diol
- 1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-
- 19-Nor-1,25-dihydroxyvitamin D<sub>2</sub>
- 19-Nor-1α-25-dihydroxyvitamin D2
- 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1α,3β,7E,22E)-
- 1α,25-Dihydroxy-19-nor-vitamin D<sub>2</sub>
- Zemplar
- Paricalcitol
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
Paricalcitol
CAS:Other vitamins and their derivatives, nesoiFormula:C27H44O3Color and Shape:White Off-White PowderMolecular weight:416.32905Paricalcitol
CAS:Formula:C27H44O3Purity:≤ 0.1%Color and Shape:White to off-white crystalline powderMolecular weight:416.642Paricalcitol
CAS:<p>Paricalcitol is a vitamin D receptor agonist.</p>Formula:C27H44O3Purity:98.59% - 99.84%Color and Shape:SolidMolecular weight:416.64Paricalcitol
CAS:Controlled Product<p>Stability Light Sensitive, Temperature Sensitive<br>Applications Synthetic analog of vitamin D. Antihyperparathyroid.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sidek, H., et al.: Biochim. Biophys. Acta, 801, 26 (1984), Ciftci, M., et al.: J. Pharmacol., 54, 275 (2002),<br></p>Formula:C27H44O3Color and Shape:NeatMolecular weight:416.64Paricalcitol-d6
CAS:Controlled Product<p>Applications Labelled Paricalcitol (P195300). Synthetic analog of vitamin D. Antihyperparathyroid.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sidek, H., et al.: Biochim. Biophys. Acta, 801, 26 (1984), Ciftci, M., et al.: J. Pharmacol., 54, 275 (2002),<br></p>Formula:C27D6H38O3Color and Shape:NeatMolecular weight:422.673Paricalcitol
CAS:<p>Paricalcitol is a drug that is used to treat congestive heart failure in patients with chronic kidney disease. It works by inhibiting the apoptosis pathway, which is important for regulating cell growth and death. Paricalcitol inhibits the production of growth factor-β1, which is known to be involved in the progression of congestive heart failure. Paricalcitol also has been shown to inhibit oxidative injury caused by ischemia–reperfusion injury and to inhibit toll-like receptor 4 signaling pathways. This drug has been shown to have long-term efficacy in experimental models of heart failure, including a rotarod test and an experimental model of kidney fibrosis.</p>Formula:C27H44O3Purity:Min. 95%Color and Shape:PowderMolecular weight:416.64 g/mol
